These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23112426)

  • 1. Effects of pravastatin on the pharmacokinetic parameters of nimodipine after oral and intravenous administration in rats: possible role of CYP3A4 inhibition by pravastatin.
    Lee CK; Choi JS; Choi DH
    Indian J Pharmacol; 2012; 44(5):624-8. PubMed ID: 23112426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein.
    Cho YA; Choi JS; Burm JP
    Pharmacol Rep; 2011; 63(4):1066-73. PubMed ID: 22001996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine.
    Choi JS; Choi I; Choi DH
    Pharmacol Rep; 2013; 65(5):1422-30. PubMed ID: 24399740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.
    Choi JS; Piao YJ; Kang KW
    Arch Pharm Res; 2011 Apr; 34(4):607-13. PubMed ID: 21544726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin.
    Choi DH; Choi JS; Li C; Choi JS
    Pharmacol Rep; 2011; 63(6):1574-82. PubMed ID: 22358108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
    Yang SH; Choi JS; Choi DH
    Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin.
    Choi SJ; Shin SC; Choi JS
    Arch Pharm Res; 2011 Feb; 34(2):309-15. PubMed ID: 21380815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
    Lee CK; Choi JS; Choi DH
    Pharmacol Rep; 2015 Feb; 67(1):44-51. PubMed ID: 25560574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine.
    Li C; Choi DH; Choi JS
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):99-108. PubMed ID: 22210483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats.
    Choi JS; Choi I; Choi DH
    Eur J Drug Metab Pharmacokinet; 2016 Jun; 41(3):231-8. PubMed ID: 25549928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin.
    Hong SP; Yang JS; Han JY; Ha SI; Chung JW; Koh YY; Chang KS; Choi DH
    J Pharm Pharmacol; 2011 Jan; 63(1):129-35. PubMed ID: 21189658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of kaempferol to increase bioavailability and pharmacokinetics of nifedipine in rats.
    Park JW; Choi JS
    Chin J Nat Med; 2019 Sep; 17(9):690-697. PubMed ID: 31526504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin.
    Cho YA; Lee W; Choi JS
    Pharmazie; 2012 Feb; 67(2):124-30. PubMed ID: 22512082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced nimodipine bioavailability after oral administration of nimodipine with morin, a flavonoid, in rabbits.
    Choi JS; Burm JP
    Arch Pharm Res; 2006 Apr; 29(4):333-8. PubMed ID: 16681041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
    Li C; Lim SC; Kim J; Choi JS
    Eur J Drug Metab Pharmacokinet; 2011 Sep; 36(3):175-82. PubMed ID: 21442417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of licochalcone A on the bioavailability and pharmacokinetics of nifedipine in rats: possible role of intestinal CYP3A4 and P-gp inhibition by licochalcone A.
    Choi JS; Choi JS; Choi DH
    Biopharm Drug Dispos; 2014 Oct; 35(7):382-90. PubMed ID: 24903704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by baicalein.
    Li C; Kim M; Choi H; Choi J
    Arch Pharm Res; 2011 Nov; 34(11):1965-72. PubMed ID: 22139696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcumin.
    Lee CK; Ki SH; Choi JS
    Biopharm Drug Dispos; 2011 May; 32(4):245-51. PubMed ID: 21506134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats.
    Choi JS; Choi JS; Choi DH
    Pharmazie; 2013 Nov; 68(11):882-8. PubMed ID: 24380237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin.
    Choi DH; Li C; Choi JS
    J Pharm Pharmacol; 2010 Jul; 62(7):908-14. PubMed ID: 20636879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.